Coexpression of Cyclooxygenase-2 and Vascular Endothelial Growth Factor in Gastrointestinal Stromal Tumor: Possible Relations to Pathological Parameters and Clinical Behavior

被引:0
作者
Miao, Ruizheng [3 ]
Liu, Naiqing [3 ]
Wang, Yongkang [1 ,2 ]
Li, Leping [3 ]
Yu, Xiaobo [3 ]
Jiang, Yanming [3 ]
Li, Jianfeng [1 ,2 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Pathol, Jinan, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Cent Lab, Jinan, Peoples R China
[3] Shandong Univ, Shandong Prov Hosp, Dept Surg, Jinan, Peoples R China
关键词
Gastrointestinal Stromal Tumor; Cyclooxygenase-2; Vascular Endothelial Growth Factor; Expression;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Currently, the clinicopathological significance of coexpression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in gastrointestinal stromal tumors (GISTs) has not been fully described. Methodology: The present study was designed to investigate the co-expression of the two markers and its significance in 54 patients with GIST by means of immunohistochemistry. Results: We demonstrated that the expressions of COX-2 and VEGF were significantly higher in malignant GIST than those in benign and potentially malignant GIST (p<0.01). A significant correlation was found between COX-2 and VEGF expression. In addition, the expressions of COX-2 and VEGF were significantly correlated with pattern of tumor growth, the size of tumors, and the central necrosis of tumors (P<0.01 or P<0.05). Five-year survival rates were much lower in patterns with high expression of COX-2 and VEGF than those with low expression (p<0.01). Overexpression of COX-2 and VEGF in GIST may enhance the possibility of growth, invasion, and metastasis. Conclusions: The levels of COX-2 and VEGF expression can be used as objective parameters in distinguishing benign from malignant, judging the malignant degree, and predicting the prognosis of patients with GIST.
引用
收藏
页码:2012 / 2015
页数:4
相关论文
共 21 条
  • [1] Gastrointestinal stromal tumor workshop
    Berman, J
    O'Leary, TJ
    [J]. HUMAN PATHOLOGY, 2001, 32 (06) : 578 - 582
  • [2] FUKUNAGA S, 2007, ONCOLOGY, V71, P204
  • [3] Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study
    Goettsch, WG
    Bos, SD
    Breekveldt-Postma, N
    Casparie, M
    Herings, RMC
    Hogendoorn, PCW
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (18) : 2868 - 2872
  • [4] Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters
    Gumurdulu, Derya
    Erdogan, Seyda
    Kayaselcuk, Fazilet
    Seydaoglu, Gulsah
    Parsak, Cem K.
    Demircan, Orhan
    Tuncer, Ilhan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (03) : 426 - 431
  • [5] Prognostic significance of angiogenesis in gastrointestinal stromal tumor
    Imamura, Masakazu
    Yamamoto, Hidetaka
    Nakamura, Norimoto
    Oda, Yoshinao
    Yao, Takashi
    Kakeji, Yoshihiro
    Baba, Hideo
    Maehara, Yoshihiko
    Tsuneyoshi, Masazumi
    [J]. MODERN PATHOLOGY, 2007, 20 (05) : 529 - 537
  • [6] Disease progression following imatinib failure in gastrointestinal stromal tumors: Role of surgical therapy
    Jamali, Faek R.
    Darwiche, Sophie S.
    El-Kinge, Nizar
    Tawil, Ayman
    Soweid, Assaad M.
    [J]. ONCOLOGIST, 2007, 12 (04) : 438 - 442
  • [7] Kindblom LG, 1998, AM J PATHOL, V152, P1259
  • [8] Loong Herbert H. F., 2007, Hong Kong Medical Journal, V13, P61
  • [9] Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy
    Maki R.G.
    [J]. Current Treatment Options in Gastroenterology, 2004, 7 (1) : 13 - 17
  • [10] Gastrointestinal stromal tumors: Recent advances in understanding of their biology
    Miettinen, M
    Sarlomo-Rikala, M
    Lasota, J
    [J]. HUMAN PATHOLOGY, 1999, 30 (10) : 1213 - 1220